Risk Factors and Outcomes of Immune-Mediated Encephalitis Following Exposure to Nivolumab

Part of paid clinical trials in Princeton, New Jersey.

Sponsor
Bristol-Myers Squibb
Study ID
NCT02856451
Status
Completed

Conditions

  • Encephalitis

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Nivolumab — BIOLOGICAL
    Specified dose on specified days

Study Details

A case series analysis of encephalitis events reported to the Sponsor for patients treated with nivolumab to assess the risk factors and outcomes of immune-mediated encephalitis.

Key Dates

First listed
Aug 4, 2016
Start date
Dec 9, 2015
Status verified
Jun 2022
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020

Study Design

Enrollment
486 participants (actual)

Arms

  • Arm: Patients Treated with Nivolumab followed by Encephalitis Event
    Case series reported to the sponsor from various health care facilities

Primary Outcome Measure

Outcomes of Encephalitis [ Time Frame: 1 year ]

Locations (1)

FacilityCityStateZIPSite coordinators
Local InstitutionPrincetonNew Jersey08540-

Related Studies